Eclampsia is the onset of seizures (convulsions) in a woman with pre-eclampsia.[1] Pre-eclampsia is a hypertensive disorder of pregnancy that presents with three main features: new onset of high blood pressure, large amounts of protein in the urine or other organ dysfunction, and edema.[7][8][9] If left untreated, pre-eclampsia can result in long-term consequences for the mother, namely increased risk of cardiovascular diseases and associated complications.[10] In more severe cases, it may be fatal for both the mother and the fetus.[11]
Low dose aspirin is recommended to prevent pre-eclampsia and eclampsia in those at high risk.[12] Other preventative recommendations include calcium supplementation in areas with low calcium intake and treatment of prior hypertension with anti-hypertensive medications.[2][3] Exercise during pregnancy may also be useful.[1] The use of intravenous or intramuscular magnesium sulfate improves outcomes in those with severe pre-eclampsia and eclampsia and is generally safe.[4][13] Treatment options include blood pressure medications such as hydralazine and emergency delivery of the baby either vaginally or by cesarean section.[1]
Pre-eclampsia is estimated to globally affect about 5% of deliveries while eclampsia affects about 1.4% of deliveries.[5] In the developed world eclampsia rates are about 1 in 2,000 deliveries due to improved medical care whereas in developing countries it can impact 10–30 times as many women.[1][14] Hypertensive disorders of pregnancy are one of the most common causes of death in pregnancy.[14] They resulted in 46,900 deaths in 2015.[6]Maternal mortality due to eclampsia occurs at a rate of approximately 0–1.8% of cases in high-income countries and up to 15% of cases in low- to middle- income countries.[15] The word eclampsia is from the Greek term for lightning.[16] The first known description of the condition was by Hippocrates in the 5th century BC.[16]
^ abHenderson, JT; Whitlock, EP; O'Connor, E; Senger, CA; Thompson, JH; Rowland, MG (20 May 2014). "Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 160 (10): 695–703. doi:10.7326/M13-2844. PMID24711050. S2CID33835367.
^ abAbalos, E; Cuesta, C; Grosso, AL; Chou, D; Say, L (September 2013). "Global and regional estimates of preeclampsia and eclampsia: a systematic review". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 170 (1): 1–7. doi:10.1016/j.ejogrb.2013.05.005. PMID23746796.
^McDonald, SD; Lutsiv, O; Dzaja, N; Duley, L (August 2012). "A systematic review of maternal and infant outcomes following magnesium sulfate for pre-eclampsia/eclampsia in real-world use". International Journal of Gynaecology and Obstetrics. 118 (2): 90–96. doi:10.1016/j.ijgo.2012.01.028. PMID22703834. S2CID20361780.
^ abArulkumaran, N.; Lightstone, L. (December 2013). "Severe pre-eclampsia and hypertensive crises". Best Practice & Research Clinical Obstetrics & Gynaecology. 27 (6): 877–884. doi:10.1016/j.bpobgyn.2013.07.003. PMID23962474.